ASSESSMENT OF THE COST-EFFECTIVENESS OF RISK FACTOR GUIDED PROPHYLAXIS WITH PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN COLOMBIAN INFANTS BORN AT 32-35 WEEKS' GESTATIONAL AGE Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Rodriguez-Martinez, CE
  • Ordonez, J
  • Carbonell-Estrany, X
  • Fullarton, J
  • Keary, I
  • Rodgers-Gray, B
  • D'Apremont, I
  • Espinosa, SM
  • Ribeiro, PA
  • Stein, R
  • Vain, N
  • Tarride, Jean-Eric
  • Paes, B

publication date

  • December 2023